264 related articles for article (PubMed ID: 15791290)
1. The cardioprotective effect of dual metallopeptidase inhibition: respective roles of endogenous kinins and natriuretic peptides.
Dumoulin MJ; Adam A; Burnett J; Heublein D; Yamaguchi N; Lamontagne D
Can J Physiol Pharmacol; 2005 Feb; 83(2):166-73. PubMed ID: 15791290
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
[TBL] [Abstract][Full Text] [Related]
3. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker.
Wang CH; Leung N; Lapointe N; Szeto L; Uffelman KD; Giacca A; Rouleau JL; Lewis GF
Circulation; 2003 Apr; 107(14):1923-9. PubMed ID: 12668518
[TBL] [Abstract][Full Text] [Related]
4. Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction.
Blais C; Lapointe N; Rouleau JL; Clément R; Gervais N; Geadah D; Adam A
Peptides; 2001 Jun; 22(6):953-62. PubMed ID: 11390026
[TBL] [Abstract][Full Text] [Related]
5. Local inhibition of bradykinin degradation in ischemic hearts.
Linz W; Martorana PA; Schölkens BA
J Cardiovasc Pharmacol; 1990; 15 Suppl 6():S99-109. PubMed ID: 1697370
[TBL] [Abstract][Full Text] [Related]
6. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
[TBL] [Abstract][Full Text] [Related]
7. Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies.
Linz W; Wiemer G; Schölkens BA
Diabetes; 1996 Jan; 45 Suppl 1():S51-8. PubMed ID: 8529801
[TBL] [Abstract][Full Text] [Related]
8. The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.
Seccia TM; Belloni AS; Guidolin D; Sticchi D; Nussdorfer GG; Pessina AC; Rossi GP
J Hypertens; 2006 Jul; 24(7):1419-27. PubMed ID: 16794493
[TBL] [Abstract][Full Text] [Related]
9. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
[TBL] [Abstract][Full Text] [Related]
10. Effects of captopril and omapatrilat on early post-myocardial infarction survival and cardiac hemodynamics in rats: interaction with cardiac cytokine expression.
Blais C; Lapointe N; Rouleau JL; Clément R; Bachvarov DR; Adam A
Can J Physiol Pharmacol; 2002 Jan; 80(1):48-58. PubMed ID: 11911226
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed.
Dumoulin MJ; Adam A; Rouleau JL; Lamontagne D
J Cardiovasc Pharmacol; 2001 Apr; 37(4):359-66. PubMed ID: 11300648
[TBL] [Abstract][Full Text] [Related]
12. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
Sulpizio AC; Pullen MA; Edwards RM; Brooks DP
J Pharmacol Exp Ther; 2004 Jun; 309(3):1141-7. PubMed ID: 14769834
[TBL] [Abstract][Full Text] [Related]
13. Bradykinin promotes ischemic norepinephrine release in guinea pig and human hearts.
Hatta E; Maruyama R; Marshall SJ; Imamura M; Levi R
J Pharmacol Exp Ther; 1999 Mar; 288(3):919-27. PubMed ID: 10027827
[TBL] [Abstract][Full Text] [Related]
14. Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues.
Nolly H; Miatello R; Damiani MT; Abate CD
Immunopharmacology; 1997 Jun; 36(2-3):185-91. PubMed ID: 9228545
[TBL] [Abstract][Full Text] [Related]
15. Haemodynamic and cardiac effects of kinin B1 and B2 receptor stimulation in conscious instrumented dogs.
Bélichard P; Loillier B; Paquet JL; Luccarini JM; Pruneau D
Br J Pharmacol; 1996 Apr; 117(7):1565-71. PubMed ID: 8730755
[TBL] [Abstract][Full Text] [Related]
16. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.
Liu YH; Yang XP; Sharov VG; Nass O; Sabbah HN; Peterson E; Carretero OA
J Clin Invest; 1997 Apr; 99(8):1926-35. PubMed ID: 9109437
[TBL] [Abstract][Full Text] [Related]
17. Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway.
Wolfrum S; Richardt G; Dominiak P; Katus HA; Dendorfer A
Br J Pharmacol; 2001 Sep; 134(2):370-4. PubMed ID: 11564655
[TBL] [Abstract][Full Text] [Related]
18. Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat.
Braun C; Kleemann T; Hilgenfeldt U; Riester U; Rohmeiss P; van der Woude FJ
Kidney Int; 2002 Jun; 61(6):2149-56. PubMed ID: 12028455
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotective actions of bradykinin in myocardial ischemia and left ventricular hypertrophy.
Linz W; Wiemer G; Schölkens BA
Braz J Med Biol Res; 1994 Aug; 27(8):1949-54. PubMed ID: 7749386
[TBL] [Abstract][Full Text] [Related]
20. A study of the mediators involved in the protection induced by exogenous kinins in the isolated rat heart.
Lagneux C; Adam A; Lamontagne D
Int Immunopharmacol; 2003 Oct; 3(10-11):1511-8. PubMed ID: 12946448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
